🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 7 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
09/09/2024 31,59 32,30 31,25 31,42 -0,38% 3,32% 456.400
06/09/2024 31,64 31,98 30,59 31,54 -0,19% 4,39% 642.800
05/09/2024 33,67 33,90 30,41 31,60 -5,92% 10,37% 820.000
04/09/2024 33,66 33,77 32,72 33,59 +0,54% 3,12% 463.100
03/09/2024 35,12 35,99 33,22 33,41 -5,41% 7,89% 537.000
30/08/2024 35,68 35,72 34,44 35,32 -0,59% 3,59% 358.200
29/08/2024 35,61 36,32 35,36 35,53 +0,97% 2,68% 457.900
28/08/2024 35,00 35,64 34,88 35,19 -0,37% 2,17% 403.400
27/08/2024 34,87 35,56 34,15 35,32 +1,17% 4,04% 646.100
26/08/2024 35,45 35,91 34,36 34,91 +2,23% 4,37% 433.100
23/08/2024 33,76 34,58 33,49 34,15 +2,15% 3,23% 431.400
22/08/2024 34,03 34,03 32,84 33,43 -1,47% 3,50% 355.100
21/08/2024 34,49 34,54 33,86 33,93 -1,34% 1,97% 469.000
20/08/2024 34,64 34,64 33,39 34,39 -0,20% 3,62% 334.800
19/08/2024 33,47 34,62 33,28 34,46 +3,11% 4,02% 409.400
16/08/2024 33,00 33,46 32,47 33,42 +1,15% 3,00% 431.400
15/08/2024 32,66 33,19 32,39 33,04 +4,00% 2,45% 521.400
14/08/2024 31,97 32,23 30,91 31,77 -0,31% 4,13% 449.000
13/08/2024 31,54 32,06 30,87 31,87 +1,79% 3,76% 449.200
12/08/2024 31,70 32,03 30,08 31,31 +0,06% 6,15% 483.400
09/08/2024 29,38 33,23 29,02 31,29 -3,57% 14,35% 725.900
08/08/2024 31,86 32,53 30,65 32,45 +1,88% 5,90% 504.400
07/08/2024 32,75 32,75 31,63 31,85 -0,75% 3,42% 937.800
06/08/2024 31,14 32,83 30,81 32,09 +3,52% 6,49% 584.200
05/08/2024 31,24 31,59 30,31 31,00 -3,70% 4,10% 657.100
02/08/2024 30,81 32,31 30,40 32,19 -1,53% 6,20% 434.400
01/08/2024 33,87 34,14 32,38 32,69 -3,43% 5,21% 477.700
31/07/2024 33,22 34,52 32,76 33,85 +2,48% 5,30% 377.800
30/07/2024 32,80 33,31 32,20 33,03 +1,57% 3,38% 653.800
29/07/2024 34,08 34,08 32,18 32,52 -4,61% 5,58% 478.800